Pharmaceutical - UK, Diabetes

Filter

Current filters:

UKDiabetes

Popular Filters

SMC accepts Eylea and Onglyza for use in NHS Scotland

SMC accepts Eylea and Onglyza for use in NHS Scotland

13-11-2014

The Scottish Medicines Consortium (SMC) has accepted German drugmaker Bayer’s Eylea (aflibercept solution…

AstraZenecaBayerDiabetesEyleaOnglyzaPharmaceuticalRegulationUK

Boehringer Ingelheim gets two drugs approved by Scotland’s health watchdog

14-10-2014

The UK subsidiary of German family-owned pharma major Boehringer Ingelheim announced today that, following…

Boehringer IngelheimCardio-vascularDiabetesJardiancePharmaceuticalPradaxaPricingUK

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

29-09-2014

Diabetes is a firm priority of UK-based pharma major AstraZeneca and is in no danger of being side-lined,…

AstraZenecaBydureonDiabetesForxigaInterviewsOnglyzaPharmaceuticalResearchUK

AstraZeneca’s Byetta meets primary endpoint in diabetes trial and reduces weight

AstraZeneca’s Byetta meets primary endpoint in diabetes trial and reduces weight

24-09-2014

UK-based pharma major AstraZeneca has announced new research showing that Byetta (exenatide) added to…

AstraZenecaByettaDiabetesGlucagonPharmaceuticalResearchUK

UK NICE wants more info on type 2 diabetes drug Jardiance

UK NICE wants more info on type 2 diabetes drug Jardiance

28-08-2014

In a new draft guidance issued today, the UK drugs watchdog the National Institute for Health and Care…

Boehringer IngelheimDiabetesEli LillyJardiancePharmaceuticalPricingRegulationUK

Insulin offers new hope for the treatment of acute pancreatitis

22-08-2014

Acute pancreatitis involves the pancreas digesting itself resulting in severe abdominal pain, vomiting…

DiabetesInflammatory diseasesPancreas disordersPharmaceuticalResearchUK

UK’s NICE approves Janssen’s Invokana for type 2 diabetes

UK’s NICE approves Janssen’s Invokana for type 2 diabetes

25-06-2014

The UK’s National Institute for Health and Care Excellence (NICE) has issued new final guidance recommending…

DiabetesInvokanaJanssenPharmaceuticalRegulationUK

ADA 2014: GSK presents new data for once-weekly Tanzeum in type 2 diabetes

ADA 2014: GSK presents new data for once-weekly Tanzeum in type 2 diabetes

15-06-2014

Patients enrolled in of four randomized Phase III studies who remained on Tanzeum/Eperzan (albiglutide),…

Anti-diabetic drugsDiabetesGlaxoSmithKlineGSKMajorPharmaceuticalResearchStudy protocolStudy protocolTanzeumUK

AstraZeneca’s Bydureon controls diabetes better than insulin glargine

AstraZeneca’s Bydureon controls diabetes better than insulin glargine

30-05-2014

Anglo-Swedish pharma major AstraZeneca has announced that Bydureon (exenatide once-weekly injection)…

Anti-diabetic drugsAstraZenecaBydureonDiabetesGlucagonPharmaceuticalResearchUK

UK’s NICE backs Janssen’s Invokana for type 2 diabetes

16-05-2014

Janssen, a subsidiary of US health care giant Johnson & Johnson, said today that it welcomes the publication…

DiabetesInvokanaJanssenJohnson & JohnsonPharmaceuticalPricingRegulationUK

Pharma Summit: Merck’s European president Bruno Strigini highlights importance of innovation

Pharma Summit: Merck’s European president Bruno Strigini highlights importance of innovation

17-03-2014

The president of pharma giant Merck & Co’s (NYSE: MRK) operations in Europe and Canada Bruno Strigini…

Anti-viralsCanadaDiabetesEuropeInterviewsMerck & CoMK-3475OncologyPharmaceuticalRegulationUKVaccines

AstraZeneca’s diabetes drug Xigduo launched in UK

AstraZeneca’s diabetes drug Xigduo launched in UK

11-03-2014

Anglo-Swedish drug major AstraZeneca’s type 2 diabetes drug Xigduo is now available in the UK.

AstraZenecaDiabetesPharmaceuticalRegulationUKXigduo

Novo Nordisk’s novel therapy could offer better outcomes for type 2 diabetes patients

Novo Nordisk’s novel therapy could offer better outcomes for type 2 diabetes patients

05-03-2014

Danish insulin giant Novo Nordisk has presented positive data at the Diabetes UK conference from its…

DenmarkDiabetesIDegLiraNovo NordiskPharmaceuticalResearchUK

Takeda’s new diabetes drug Vipidia debuts in UK

26-02-2014

Japan’s largest drugmaker Takeda Pharmaceuticals this morning launched its new type 2 diabetes drug…

alogliptinDiabetesMarkets & MarketingNorthern EuropePharmaceuticalTakeda PharmaceuticalsUKVipidia

NICE consults on draft guidance backing Invokana, as drug debuts in the UK

24-02-2014

UK drugs watchdog the National Institute for Health and Care Excellence is currently appraising Invokana…

DiabetesInvokanaJanssen-CilagJohnson & JohnsonMarkets & MarketingNorthern EuropePharmaceuticalPricingRegulationUK

Novo Nordisk launches diabetes collaboration focused on integrated care with London partners

Novo Nordisk launches diabetes collaboration focused on integrated care with London partners

27-01-2014

A unique collaboration between leading London hospitals and Danish insulin giant Novo Nordisk (NOV: N)…

DiabetesHealthcareNovo NordiskPharmaceuticalUK

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

16-12-2013

Secrets of how Bristol-Myers Squibb and AstraZeneca arranged a behind-the-scenes deal to buy Amylin were…

AmylinAstraZenecaBristol-Myers SquibbDiabetesInterviewsLegalMergers & AcquisitionsPharmaceuticalUKUSA

Back to top